Doug Nissinoff is currently the Chief Business Officer at Oral Biolife Inc., where they are pioneering innovative periodontal care with the groundbreaking product Ambrilux Gel. With a robust background in biotech and venture capital, Doug has held roles such as Biotech Investor Relations Analyst at Stern Investor Relations and Principal at Renegade BioConsulting, a global executive consultancy they founded. They are also a Managing Partner and Founder at Intelligence Ventures, focusing on investments at the intersection of AI and healthcare. Doug's academic journey continues at Georgetown University, where they maintain a 3.82 GPA.
This person is not in the org chart
This person is not in any teams
This person is not in any offices